REGEN BIOPHARMA, INC. (RGBP) Operating margin 2017–2025
REGEN BIOPHARMA, INC. (RGBP) operating margin by fiscal year — reported operating income divided by reported revenue.
-143.1%FY2025 · since FY2017: -2282.6% → -143.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -143.1% | +33.3 pp |
| FY2024 | -176.4% | +114.0 pp |
| FY2023 | -290.4% | -19.8 pp |
| FY2022 | -270.6% | +57.5 pp |
| FY2021 | -328.1% | -137.8 pp |
| FY2020 | -190.3% | +497.7 pp |
| FY2019 | -688.0% | +737.8 pp |
| FY2018 | -1425.8% | +856.8 pp |
| FY2017 | -2282.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RGBP financial trends
RGBP RevenueRGBP Net incomeRGBP Net marginRGBP Gross profitRGBP Gross marginRGBP Operating incomeRGBP Operating cash flowRGBP Free cash flowRGBP Capital expendituresRGBP Return on equityRGBP Stock buybacksRGBP Dividends paidRGBP Total assetsRGBP Total liabilitiesRGBP Shareholders’ equityRGBP overview →